Cited by 258Mitochondrial Function and PathologyMetabolism and Genetic DisordersGenomics and Rare Diseases

The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.

Mitochondrial disorders: Prevalence, myths and advances

Thorburn, D. R.·2004·Journal of Inherited Metabolic Disease

Abstract

Summary: Disorders of mitochondrial oxidative phosphorylation (OXPHOS) are renowned for their variability in clinical features and genetic causes. This makes it difficult to determine their true prevalence, but recent studies have documented a minimum birth prevalence of 13.1/100 000 or 1/7634 for oxidative phosphorylation disorders with onset at any age. This clearly remains an underestimate but it indicates that oxidative phosphorylation disorders can be regarded as the most common group of inborn errors of metabolism. Pathogenic mutations causing human oxidative phosphorylation disorders have now been identified in more than 30 of the 37 mitochondrial DNA genes and in more than 30 nuclear genes. Most of the nuclear gene defects cause autosomal recessive diseases, but autosomal dominant and X‐linked disorders also occur. It is likely that at least another 30, and perhaps over 100, nuclear‐encoded oxidative phosphorylation disorders await identification. Oxidative phosphorylation genetics are complex and there appear to be a number of common misconceptions about mitochondrial DNA mutations that may impede optimal investigation and management of patients. In our experience, mitochondrial DNA mutations are not a negligible cause of OXPHOS disorders in children but account for 20–25% of cases. Similarly, a family history suggesting maternal inheritance is the exception rather than the norm for children with mitochondrial DNA mutations, many of whom have de novo mutations. Only some mitochondrial DNA mutations disappear from cultured cells, so deficient enzyme activity in fibroblasts does not imply the presence of a nuclear defect. Finally, it is still widely thought that there are very few reproductive options that can be offered to women at risk of transmitting a mitochondrial DNA mutation. While a cautious approach is needed, there is now a consensus that prenatal diagnosis should be offered to some women, particularly those at lower recurrence risk. Preimplantation genetic diagnosis can also be an option.

Overview

Integrity signals

Registry

Crossref · 10.1023/b:boli.0000031098.41409.55

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mitochondrial diseases are caused by genetic mutations in mitochondrial or nuclear DNA that affect the function of the mitochondrial respiratory chain, leading to defective oxidative phosphorylation.

    “Mitochondrial diseases are caused by genetic mutations in mitochondrial or nuclear DNA that affect the function of the mitochondrial respiratory chain, thereby leading to defective oxidative phosphorylation (Ishikawa and Nakada, 2021; Parikh et al., 2015; Thorburn, 2004).”

Citations

Cites

Flagged first, then by citations

1 of the 55 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Online Mendelian Inheritance in Man 2000. <http://www.ncbi.nlm.nih.gov/omim/>.

Cited by

Sorted by citations

Metadata

Authors
Thorburn, D. R.
Affiliations
Royal Children's Hospital (AU)
Corresponding author
Thorburn, D. R.
Venue
Journal of Inherited Metabolic Disease
Publisher
Wiley
Published
2004-05
Volume
27
Issue
3
Pages
349-362
ISSN
  • 0141-8955 (ISSN-L)
  • 1573-2665
OpenAlex
W2047834942
Cited by
258
References
55
Citations by year
2026: 8 · 2025: 10 · 2024: 11 · 2023: 11 · 2022: 15 · 2021: 13 · 2020: 9 · 2019: 8 · 2018: 12 · 2017: 9 · 2016: 19 · 2015: 14 · 2014: 9 · 2013: 20 · 2012: 11
FWCI
0.76
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Inherited Metabolic Disease (publishedVersion)
  • PubMed (publishedVersion)
Funders
Medical Research Council
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
mitochondrial disease, oxidative phosphorylation disorders, mitochondrial DNA mutations, birth prevalence, inborn errors of metabolism, maternal inheritance, de novo mutations, prenatal diagnosis, preimplantation genetic diagnosis, fibroblast enzyme activity
MeSH terms
Humans, Risk Factors, Prevalence, Mitochondrial Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review